All In Biotech

Drug Trial Radar · NCT07737769

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase I Non-Randomized Study of TP53 Reactivation With Arsenic Trioxide in Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Nov 2028

Study completion Nov 2029

Sponsor

Lead sponsor
University of Michigan Rogel Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, best dose and how well arsenic trioxide works to prevent relapse in patients undergoing allogenic stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Chemotherapy drugs, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic trioxide may be safe, tolerable and/or effective in preventing relapse in patients undergoing allogenic stem cell transplant for AML or MDS.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Given IV

  • Arsenic TrioxideDrug

    Given IV

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • BusulfanDrug

    Given IV

  • FludarabineDrug

    Given fludarabine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicitiesTime frame: From baseline to day 35 post hematopoietic stem cell transplant (HCT)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.